3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
101
Neoplasms, Plasma Cell
12
Recurrence
9
Lymphoma
8
Immunoglobulin Light-chain Amyloidosis
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myeloid, Acute
5
Lymphoma, Mantle-Cell
4
Waldenstrom Macroglobulinemia
3
Paraproteinemias
3
Hematologic Neoplasms
3
Amyloidosis
3
Renal Insufficiency
2
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Burkitt Lymphoma
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
olaparib
4
Pluvicto
4
Abiraterone Acetate
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
enzalutamide
2
darolutamide
2
Prednisone
2
Prednisolone
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
fluciclovine F-18
1
enfortumab vedotin
1
cabozantinib
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
1 year
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled